{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:03:19Z","timestamp":1788454999600,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":2411,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Lineberger Comprehensive Cancer Center"},{"name":"Clinical and Translational Science Award","award":["5UL1RR025747-04"],"award-info":[{"award-number":["5UL1RR025747-04"]}]},{"DOI":"10.13039\/100000057","name":"NIH-National Institute of General Medical Sciences","doi-asserted-by":"crossref","award":["T32GM081057"],"award-info":[{"award-number":["T32GM081057"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NIH SPORE in Breast Cancer","award":["5P50CA058223"],"award-info":[{"award-number":["5P50CA058223"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1093\/annonc\/mdt018","type":"journal-article","created":{"date-parts":[[2013,2,15]],"date-time":"2013-02-15T01:29:57Z","timestamp":1360891797000},"page":"1472-1478","source":"Crossref","is-referenced-by-count":103,"title":["CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel"],"prefix":"10.1016","volume":"24","author":[{"given":"D.L.","family":"Hertz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.A.","family":"Motsinger-Reif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Drobish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.S.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.L.","family":"McLeod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.A.","family":"Carey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.C.","family":"Dees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1093\/annonc\/mdt018_bb0010","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s12094-011-0686-x","article-title":"Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials","volume":"13","author":"Gines","year":"2011","journal-title":"Clin Transl Oncol"},{"issue":"16","key":"10.1093\/annonc\/mdt018_bb0015","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1200\/JCO.2005.10.517","article-title":"Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28","volume":"23","author":"Mamounas","year":"2005","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdt018_bb0020","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","volume":"21","author":"Citron","year":"2003","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdt018_bb0025","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/oxfordjournals.annonc.a059220","article-title":"Paclitaxel-induced neuropathy","volume":"6","author":"Postma","year":"1995","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1093\/annonc\/mdt018_bb0030","first-page":"107","article-title":"Neurotoxicity of taxol","volume":"1993","author":"Rowinsky","year":"1993","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"4 Suppl. 3","key":"10.1093\/annonc\/mdt018_bb0035","first-page":"1","article-title":"Clinical toxicities encountered with paclitaxel (taxol)","volume":"20","author":"Rowinsky","year":"1993","journal-title":"Semin Oncol"},{"issue":"10","key":"10.1093\/annonc\/mdt018_bb0040","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1002\/cncr.11375","article-title":"Weekly, high-dose paclitaxel in advanced lung carcinoma","volume":"97","author":"Akerley","year":"2003","journal-title":"Cancer"},{"issue":"25","key":"10.1093\/annonc\/mdt018_bb0045","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1200\/JCO.2011.39.8446","article-title":"Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer","volume":"30","author":"Schneider","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1093\/annonc\/mdt018_bb0050","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/00001813-200311000-00003","article-title":"Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h","volume":"14","author":"Mielke","year":"2003","journal-title":"Anticancer Drugs"},{"issue":"13","key":"10.1093\/annonc\/mdt018_bb0055","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1158\/1078-0432.CCR-05-0298","article-title":"Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer","volume":"11","author":"Mielke","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1093\/annonc\/mdt018_bb0060","first-page":"5543","article-title":"Selective biotransformation of taxol to 6{alpha}-hydroxytaxol by human cytochrome P450 2C8","volume":"54","author":"Rahman","year":"1994","journal-title":"Cancer Res"},{"issue":"15","key":"10.1093\/annonc\/mdt018_bb0065","first-page":"4026","article-title":"Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme","volume":"54","author":"Harris","year":"1994","journal-title":"Cancer Res"},{"issue":"1","key":"10.1093\/annonc\/mdt018_bb0070","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2125.2012.04165.x","article-title":"Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure","volume":"74","author":"Hertz","year":"2012","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"10.1093\/annonc\/mdt018_bb0075","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0959-8049(03)00126-6","article-title":"Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients","volume":"39","author":"Henningsson","year":"2003","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1093\/annonc\/mdt018_bb0080","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1124\/dmd.109.030866","article-title":"Relevance of nonsynonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation","volume":"38","author":"Rowbotham","year":"2010","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1093\/annonc\/mdt018_bb0085","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/tpj.2010.19","article-title":"Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer","volume":"11","author":"Bergmann","year":"2011","journal-title":"Pharmacogenomics J"},{"key":"10.1093\/annonc\/mdt018_bb0090","unstructured":"International HapMap Project frequency report for refSNP rs10509681 [Internet] http:\/\/hapmap.ncbi.nlm.nih.gov\/cgi-perl\/snp_details_phase3?name=rs10509681&source=hapmap28_B36&tmpl=snp_details_phase3"},{"issue":"6968","key":"10.1093\/annonc\/mdt018_bb0095","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nature02168","article-title":"The International HapMap Project","volume":"426","year":"2003","journal-title":"Nature"},{"issue":"2","key":"10.1093\/annonc\/mdt018_bb0100","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1742-7843.2008.00351.x","article-title":"Pharmacogenetic studies of paclitaxel in the treatment of ovarian cancer","volume":"104","author":"Gr\u00e9en","year":"2009","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"10.1093\/annonc\/mdt018_bb0105","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10549-012-2054-0","article-title":"CYP2C8*3 predicts benefit\/risk profile in breast cancer patients receiving neoadjuvant paclitaxel","volume":"134","author":"Hertz","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1093\/annonc\/mdt018_bb0110","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/tpj.2010.13","article-title":"Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity","volume":"11","author":"Leskela","year":"2011","journal-title":"Pharmacogenomics J"},{"key":"10.1093\/annonc\/mdt018_bb0115","year":"2010"},{"issue":"Suppl. 1","key":"10.1093\/annonc\/mdt018_bb0120","doi-asserted-by":"crossref","first-page":"S272","DOI":"10.1002\/gepi.2001.21.s1.s272","article-title":"Marker selection by Akaike information criterion and Bayesian information criterion","volume":"21","author":"Li","year":"2001","journal-title":"Genet Epidemiol"},{"issue":"3","key":"10.1093\/annonc\/mdt018_bb0125","first-page":"519","article-title":"The impact of population admixture on traditional linkage analysis","volume":"11","author":"Barnholtz-Sloan","year":"2001","journal-title":"Ethn Dis"},{"issue":"7","key":"10.1093\/annonc\/mdt018_bb0130","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/01.gim.0000179941.44494.73","article-title":"How can the evaluation of genetic tests be enhanced? Lessons learned from the ACCE framework and evaluating genetic tests in the United Kingdom","volume":"7","author":"Sanderson","year":"2005","journal-title":"Genet Med"},{"issue":"2","key":"10.1093\/annonc\/mdt018_bb0135","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s10549-010-1034-5","article-title":"Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients","volume":"124","author":"Rizzo","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"29","key":"10.1093\/annonc\/mdt018_bb0140","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1200\/JCO.2006.10.4752","article-title":"Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish randomised trial in ovarian cancer","volume":"25","author":"Marsh","year":"2007","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdt018_bb0145","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00228-011-1007-6","article-title":"Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer","volume":"67","author":"Bergmann","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1093\/annonc\/mdt018_bb0150","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1742-7843.2011.00802.x","article-title":"Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer","volume":"110","author":"Bergmann","year":"2012","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1093\/annonc\/mdt018_bb0155","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/843019","article-title":"Neurotoxicity caused by the treatment with platinum analogues","author":"Amptoulach","year":"2011","journal-title":"Chemother Res Pract"},{"issue":"5","key":"10.1093\/annonc\/mdt018_bb0160","doi-asserted-by":"crossref","first-page":"e19166","DOI":"10.1371\/journal.pone.0019166","article-title":"Genetic background of patients from a university medical center in Manhattan: implications for personalized medicine","volume":"6","author":"Tayo","year":"2011","journal-title":"PLoS ONE"},{"issue":"15 Suppl.","key":"10.1093\/annonc\/mdt018_bb0165","first-page":"1000","article-title":"Genetic associations with taxane-induced neuropathy by a genome-wide association study (GWAS) in E5103","volume":"29","author":"Schneider","year":"2011","journal-title":"ASCO Meeting Abstracts"},{"issue":"1\u20132","key":"10.1093\/annonc\/mdt018_bb0170","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jns.2011.11.009","article-title":"The relationship between race and HIV-distal sensory polyneuropathy in a large cohort of US women","volume":"315","author":"Anziska","year":"2012","journal-title":"J Neurol Sci"},{"issue":"1","key":"10.1093\/annonc\/mdt018_bb0175","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1464-5491.2011.03379.x","article-title":"Association between vitamin D and diabetic neuropathy in a nationally representative sample: results from 2001\u20132004 NHANES","volume":"29","author":"Soderstrom","year":"2012","journal-title":"Diabetic Med"},{"issue":"6","key":"10.1093\/annonc\/mdt018_bb0180","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ctrv.2011.10.008","article-title":"Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumors: a meta-analysis","volume":"38","author":"Huang","year":"2012","journal-title":"Cancer Treat Rev"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419373041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419373041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/24\/6\/1472\/430862\/mdt018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T09:05:02Z","timestamp":1624698302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419373041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S0923753419373041"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdt018","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}